As of Feb 27
| -0.69 / -0.69%|
The 7 analysts offering 12-month price forecasts for Synageva BioPharma Corp have a median target of 114.00, with a high estimate of 125.00 and a low estimate of 111.00. The median estimate represents a +15.47% increase from the last price of 98.73.
The current consensus among 7 polled investment analysts is to Buy stock in Synageva BioPharma Corp. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.